Probleme bei der Darstellung von ARIVA.DE?

  • Laden unsere Charts bei Ihnen nicht?
  • Wird unser Forum bei Ihnen nicht korrekt dargestellt?

Sie nutzen einen Adblocker, der hierfür verantwortlich ist. Hierauf hat ARIVA.DE leider keinen Einfluss. Bitte heben Sie die Blockierung von ARIVA.DE in Ihrem Adblocker auf.

Probleme bei der Darstellung von ARIVA.DE?

ITEK INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Inotek Pharmaceuticals Corporation and a Lead Plaintiff Deadline of March 7, 2017

Montag, 13.02.2017 20:30 von

PR Newswire

NEW YORK, Feb. 13, 2017 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) securities between July 23, 2015 and December 30, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/inotek-pharmaceuticals-corporation. There is no cost or obligation to you.

According to the complaint, throughout the Class Period, Inotek misrepresented the efficacy of its drug candidate trabodenoson—the only drug Inotek currently has in its clinical development pipeline—and its attendant capacity to receive New Drug Approval by the U.S. Food and Drug Administration. In particular, it is alleged that the Company made positive statements about the drug despite knowledge that the MATrX-1 phase 3 clinical trial of trabodenoson would fail to meet its primary endpoint of statistical relevance in the reduction of intraocular pressure compared with placebo.

On January 3, 2017, Inotek announced that the Phase 3 trial of trabodenoson had failed to achieve this primary endpoint. Following this news, shares of Inotek fell from a closing price of $6.10 on December 30, 2016, to a closing price of of $1.75 per share on January 3, 2017.

If you suffered a loss in Inotek Pharmaceuticals you have until March 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/inotek-pharmaceuticals-corporation.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/itek-investor-alert-the-law-offices-of-vincent-wong-reminds-investors-of-a-class-action-involving-inotek-pharmaceuticals-corporation-and-a-lead-plaintiff-deadline-of-march-7-2017-300406350.html

SOURCE The Law Offices of Vincent Wong